112 related articles for article (PubMed ID: 17409800)
21. Survivin antiapoptotic gene expression as a prognostic factor in non-small cell lung cancer: in situ hybridization study.
Karczmarek-Borowska B; Filip A; Wojcierowski J; Smoleń A; Pilecka I; Jabłonka A
Folia Histochem Cytobiol; 2005; 43(4):237-42. PubMed ID: 16382892
[TBL] [Abstract][Full Text] [Related]
22. Paclitaxel/Platinum-based perioperative chemotherapy and surgery in stage IIIA non-small cell lung cancer.
Choi IS; Oh DY; Kwon JH; Kim SI; Park SR; Bak JY; Kim JH; Kim DW; Kim YT; Kim TY; You CK; Kim YW; Heo DS; Bang YJ; Sung SW; Park CI; Kim NK
Jpn J Clin Oncol; 2005 Jan; 35(1):6-12. PubMed ID: 15681597
[TBL] [Abstract][Full Text] [Related]
23. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
24. Skip metastasis in nonsmall cell lung carcinoma: predictive markers and isolated tumor cells in N1 lymph nodes.
Prenzel KL; Baldus SE; Mönig SP; Tack D; Sinning JM; Gutschow CA; Grass G; Schneider PM; Dienes HP; Hölscher AH
Cancer; 2004 May; 100(9):1909-17. PubMed ID: 15112272
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
Gadgeel SM; Ruckdeschel JC; Heath EI; Heilbrun LK; Venkatramanamoorthy R; Wozniak A
J Thorac Oncol; 2007 Apr; 2(4):299-305. PubMed ID: 17409801
[TBL] [Abstract][Full Text] [Related]
26. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014).
Grossi F; Spizzo R; Bordo D; Cacitti V; Valent F; Rossetto C; Follador A; Di Terlizzi S; Aita M; Morelli A; Fasola G; Consiglieri C; Ceschia T; Beltrami CA; Belvedere O
J Thorac Oncol; 2010 Sep; 5(9):1354-60. PubMed ID: 20631638
[TBL] [Abstract][Full Text] [Related]
27. Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy.
Vassalou H; Stathopoulos E; Fiolitaki G; Koutsopoulos A; Voutsina A; Georgoulias V; Mavroudis D
Lung Cancer; 2013 Nov; 82(2):324-9. PubMed ID: 23993732
[TBL] [Abstract][Full Text] [Related]
28. A phase II study of docetaxel and carboplatin in Thai patients with advanced non-small-cell lung cancer.
Thongprasert S; Soorraritchingchai S; Chewaskulyong B; Charoentum C; Munprakan S
J Med Assoc Thai; 2006 Feb; 89(2):152-9. PubMed ID: 16579000
[TBL] [Abstract][Full Text] [Related]
29. Induction chemotherapy with and without recombinant human granulocyte colony-stimulating factor support in locally advanced stage IIIA/B non-small cell lung cancer.
Fischer JR; Manegold C; Bülzebruck H; Vogt-Moykopf I; Drings P
Semin Oncol; 1994 Jun; 21(3 Suppl 4):20-7. PubMed ID: 7516094
[TBL] [Abstract][Full Text] [Related]
30. Absence of prognostic significance of p21(WAF1/CIP1) protein expression in non-small cell lung cancer.
Dworakowska D; Jassem E; Jassem J; Boltze C; Wiedorn KH; Dworakowski R; Skokowski J; Jaśkiewicz K; Czestochowska E
Acta Oncol; 2005; 44(1):75-9. PubMed ID: 15848909
[TBL] [Abstract][Full Text] [Related]
31. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use.
Weber WA; Petersen V; Schmidt B; Tyndale-Hines L; Link T; Peschel C; Schwaiger M
J Clin Oncol; 2003 Jul; 21(14):2651-7. PubMed ID: 12860940
[TBL] [Abstract][Full Text] [Related]
32. Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy.
Shimizu K; Yukawa T; Okita R; Saisho S; Maeda A; Nojima Y; Nakata M
World J Surg Oncol; 2015 Feb; 13():21. PubMed ID: 25888998
[TBL] [Abstract][Full Text] [Related]
33. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
[TBL] [Abstract][Full Text] [Related]
34. Survival of patients with advanced non-small-cell lung cancer at Ubon Ratchathani Cancer Center, Thailand.
Srisam-Ang K; Podhipak A; Narksawat K; Supaattagorn P; Tipayamongkholgul M
Southeast Asian J Trop Med Public Health; 2005 Jul; 36(4):994-1006. PubMed ID: 16295558
[TBL] [Abstract][Full Text] [Related]
35. Expression of p53 gene in stage IIIA non-small cell lung cancer in patients after neoadjuvant chemotherapy with Vepesid and Cisplatin.
Mańdziuk S; Dudzisz-Sledź M; Korszeń-Pilecka I; Milanowski J; Wojcierowski J; Korobowicz E
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):154-7. PubMed ID: 15314976
[TBL] [Abstract][Full Text] [Related]
36. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.
Yoshimura N; Kudoh S; Kimura T; Mitsuoka S; Kyoh S; Tochino Y; Asai K; Kodama T; Ichimaru Y; Yana T; Hirata K
J Thorac Oncol; 2009 Mar; 4(3):371-5. PubMed ID: 19155998
[TBL] [Abstract][Full Text] [Related]
38. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
[TBL] [Abstract][Full Text] [Related]
39. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
40. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]